Skip to main navigation Skip to search Skip to main content

Is there a treatment advantage when paclitaxel and lovastatin are combined to dose anaplastic thyroid carcinoma cell lines?

  • Yoo Seung Chung
  • , Sujin Cho
  • , Hee Joo Ryou
  • , Hyeon Gun Jee
  • , June Young Choi
  • , Kwan Yoon
  • , Hyuk Jae Choi
  • , Kyu Eun Lee
  • , Young Jin Suh
  • , Seung Keun Oh
  • , Yeo Kyu Youn
  • The Catholic University of Korea, St. Vincent's Hospital
  • Gachon University
  • Seoul National University

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Is there a treatment advantage when paclitaxel and lovastatin are combined to dose anaplastic thyroid carcinoma cell lines?'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science